Literature DB >> 11096764

Blepharospasm and Hemifacial Spasm.

.   

Abstract

The main objective in the treatment of blepharospasm is to decrease or cease the unwanted, repeated forced closure of the eyelids. This is best achieved by the use of botulinum toxin. In a minority of patients, botulinum toxin is either ineffective or poorly tolerated. In this group of patients, a trial with oral medication in the following order is warranted: trihexyphenidyl, baclofen, clonazepam, and tetrabenazine. Before going to the next medication, each of these drugs should be administered at the highest tolerated dosage for a period of 1 or 2 months. If, as often happens, all pharmacologic treatment attempts fail, and the patient is too disabled to remain untreated, he or she can be referred to an experienced plastic surgeon for a myectomy of the eyelid protractors. For treatment of apraxia of eyelid opening, botulinum toxin should be administered as the first treatment. If this fails, and vision is significantly impaired, the patient may be referred to a plastic surgeon for a frontalis suspension of the eyelid. Treatments of hemifacial spasm are aimed at decreasing or ending the annoying twitches of one side of the face. In this disorder, interference with vision is not a problem unless the contralateral eye is amblyopic. Despite isolated reports of spasm relief by drugs such as carbamazepine, oral medication is unlikely to be helpful. Botulinum toxin is the preferred treatment in hemifacial spasm patients. In some patients, relief from spasms can only be obtained at the cost of an ipsilateral upper lip droop of varying severity. Patients who are dissatisfied with the results of treatment with botulinum toxin, and are not willing to tolerate their condition, can be referred to an experienced neurosurgeon for microvascular decompression of the facial nerve. Pending success of ongoing attempts to reduce adverse effects, we believe that doxorubicin chemomyectomy, a recent treatment that has been used for both facial spasm and blepharospasm, is best administered in a research setting.

Entities:  

Year:  2000        PMID: 11096764     DOI: 10.1007/s11940-000-0037-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  29 in total

1.  Botulinum therapy for apraxia of eyelid opening.

Authors:  B Katz; J H Rosenberg
Journal:  Am J Ophthalmol       Date:  1987-05-15       Impact factor: 5.258

2.  Botulinum toxin: preferred treatment for hemifacial spasm.

Authors:  M Flanders; D Chin; D Boghen
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

3.  Therapeutic trials in Meige syndrome.

Authors:  S M Gollomp; S Fahn; R E Burke; A Reches; J Ilson
Journal:  Adv Neurol       Date:  1983

4.  Pharmacology of cranial dystonia.

Authors:  C D Marsden; A E Lang; M P Sheehy
Journal:  Neurology       Date:  1983-08       Impact factor: 9.910

5.  Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984.

Authors:  R G Auger; J P Whisnant
Journal:  Arch Neurol       Date:  1990-11

6.  Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.

Authors:  J D Wirtschafter; L K McLoon
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

7.  Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.

Authors:  J Jankovic
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

8.  Cranial dystonia: double-blind crossover study of anticholinergics.

Authors:  J G Nutt; J P Hammerstad; P deGarmo; J Carter
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

9.  Microvascular decompression for hemifacial spasm.

Authors:  F G Barker; P J Jannetta; D J Bissonette; P T Shields; M V Larkins; H D Jho
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

10.  Meige disease: acute and chronic cholinergic effects.

Authors:  C M Tanner; R H Glantz; H L Klawans
Journal:  Neurology       Date:  1982-07       Impact factor: 9.910

View more
  3 in total

1.  Electroacupuncture on Hemifacial Spasm and Temporomandibular Joint Pain Co-Morbidity: A Case Report.

Authors:  Jian-Peng Huang; Zhan-Mou Liang; Qi-Wen Zou; Jie Zhan; Wen-Ting Li; Sheng Li; Kai Li; Wen-Bin Fu; Jian-Hua Liu
Journal:  Front Neurol       Date:  2022-06-28       Impact factor: 4.086

2.  Typewriter tinnitus revisited: The typical symptoms and the initial response to carbamazepine are the most reliable diagnostic clues.

Authors:  Woongsang Sunwoo; Yung Jin Jeon; Yun Jung Bae; Jeong Hun Jang; Ja-Won Koo; Jae-Jin Song
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

3.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.